ReviewIntensive care medicine2020
Myorelaxants in ARDS patients.
Review in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Deep knowledge-driven multi-modal fusion for diagnosis and prognosis of SI-ARDS.Communications medicine · 2026Article
- Neuromuscular blockade and their monitoring in the intensive care unit: a multicenter observational prospective study.Annals of intensive care · 2025Article
- Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Article
- The association between non-depolarizing neuromuscular blockade agents and survival to discharge in dogs undergoing mechanical ventilation: a multi-center retrospective study of 227 dogs (2010-2020).Frontiers in veterinary science · 2025Article
- Article
- Ensemble-Based Virtual Screening Led to the Discovery of Novel Lead Molecules as Potential NMBAs.Molecules (Basel, Switzerland) · 2024Article
- Improving management of ARDS: uniting acute management and long-term recovery.Critical care (London, England) · 2024Review
- Management of Neuromuscular Blocking Agents in Critically Ill Patients with Lung Diseases.Journal of clinical medicine · 2024Review
- Pendelluft in patients with acute respiratory distress syndrome during trigger and reverse triggering breaths.Scientific reports · 2023Article
- Effect and mechanical mechanism of spontaneous breathing on oxygenation and lung injury in mild or moderate animal ARDS.BMC pulmonary medicine · 2023Article
- Usefulness of Inhaled Sedation in Patients With Severe ARDS Due to COVID-19.Respiratory care · 2023Article
- Factors associated with mortality in mechanically ventilated patients with severe acute respiratory syndrome due to COVID-19 evolution.Critical care science · 2023Article
- Characteristics and outcomes of patients with severe COVID-19 in Indonesia: Lessons from the first wave.PloS one · 2023Observational
- Neuromuscular blocking agents and opioids are major risk factors for developing pressure injuries in patients in the intensive care unit.The Korean journal of internal medicine · 2022Article
- Neuromuscular blocking agents in the intensive care unit.The Journal of international medical research · 2022Review
- Dynamic evaluation of the pulmonary protective effects of prone position ventilation via respiratory mechanics for patients with moderate to severe acute respiratory distress syndrome.Journal of thoracic disease · 2022Article
- ARDS Clinical Practice Guideline 2021.Journal of intensive care · 2022Article
- Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial.Journal of clinical medicine · 2022Article
- c-Fos is a mechanosensor that regulates inflammatory responses and lung barrier dysfunction during ventilator-induced acute lung injury.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 5 countries.
Funding
Abstract
Neuromuscular blocking agents (NMBAs) inhibit patient-initiated active breath and the risk of high tidal volumes and consequent high transpulmonary pressure swings, and minimize patient/ ventilator asynchrony in acute respiratory distress syndrome (ARDS). Minimization of volutrauma and ventilator-induced lung injury (VILI) results in a lower incidence of barotrauma, improved oxygenation and a decrease in circulating proinflammatory markers. Recent randomized clinical trials did not reveal harmful muscular effects during a short course of NMBAs. The use of NMBAs should be considered during the early phase of severe ARDS for patients to facilitate lung protective ventilation or prone positioning only after optimising mechanical ventilation and sedation. The use of NMBAs should be integrated in a global strategy including the reduction of tidal volume, the rational use of PEEP, prone positioning and the use of a ventilatory mode allowing spontaneous ventilation as soon as possible. Partial neuromuscular blockade should be evaluated in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.